Abstract Number: 577 • 2018 ACR/ARHP Annual Meeting
Expanded Autoantibody Profiles Predict Treatment Response to Biologic Therapy in Rheumatoid Arthritis
Background/Purpose: Although biologics represent a major advance in rheumatoid arthritis (RA), many patients fail to achieve adequate responses to these agents. As previous studies have…Abstract Number: 989 • 2018 ACR/ARHP Annual Meeting
Reduction of Serum IL17F and IL22 By IL23p19 Blockade with Guselkumab Is Associated with Improvement in Joint Symptoms in Psoriatic Arthritis
Background/Purpose: Guselkumab (GUS) is a fully human monoclonal antibody that binds to the p19 subunit of IL23. In a recent Phase 2 study, GUS demonstrated…Abstract Number: 1442 • 2018 ACR/ARHP Annual Meeting
Differential Chemical Isotope Labeling Liquid Chromatography Mass Spectrometry and a Universal Metabolome Standard Reveals a Metabolome Profile with Consistent Accuracy for Rheumatoid Arthritis
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) is hampered by suboptimal accuracy of currently available serological biomarkers. Recent advancements in metabolomic profiling include dansylation liquid…Abstract Number: 1983 • 2018 ACR/ARHP Annual Meeting
Mutations Associated with Clonal Hematopoiesis of Indeterminate Potential Are Found in Peripheral Blood and Synovial Fluid Macrophages from Patients with Rheumatoid and Psoriatic Arthritis
Background/Purpose: Myeloidmutations commonly associated to neoplasia in patients who do not meet the diagnostic criteria for myelodysplastic syndrome are coined as clonal hematopoiesis of indeterminate…Abstract Number: 2775 • 2018 ACR/ARHP Annual Meeting
Neutrophil to Lymphocyte Ratio Predicts Glucocorticoid Resistance in Polymyalgia Rheumatica
Background/Purpose: Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have been demonstrated to correlate with disease activity and predict treatment response in…Abstract Number: 583 • 2018 ACR/ARHP Annual Meeting
Identification of a Protein Profile Useful to Predict Response to Methotrexate in Early Rheumatoid Arthritis Patients
Background/Purpose: Among the best known disease-modifying antirheumatic drugs, Methotrexate (MTX) is one of the most effective and widely used medications. It is used as a…Abstract Number: 1042 • 2018 ACR/ARHP Annual Meeting
Development of a Neo-Epitope Specific Assay for Serological Assessment of Type X Collagen Degradation and Its Potential Diagnostic Value for Knee Osteoarthritis
Background/Purpose: Phenotypic changes of chondrocytes toward hypertrophy might be fundamental in the pathogenesis of OA, of which type X collagen is a well-known marker. The…Abstract Number: 465 • 2017 ACR/ARHP Annual Meeting
Basement Membrane Remodeling in Rheumatoid Arthritis Associates with Disease Activity, Response to IL-6 Inhibitor Treatment and Radiographic Progression: Analysis of Two Phase III Clinical Trials
Background/Purpose: Rheumatoid arthritis (RA) is associated with neovascularization of the synovial membrane and increased risk of cardiovascular co-morbidity. The extra cellular matrix below the endothelial…Abstract Number: 758 • 2017 ACR/ARHP Annual Meeting
Identification of Biomarkers Predictive of Pulmonary Arterial Hypertension in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular abnormalities, immune system dysregulation, and fibrosis. Pulmonary arterial hypertension (PAH) affects approximately 10% of…Abstract Number: 1281 • 2017 ACR/ARHP Annual Meeting
Plasma CXCL4 As a Biomarker in Juvenile Systemic Sclerosis
Background/Purpose: Juvenile systemic sclerosis (jSSc) is a severe and heterogeneous autoimmune vasculopathy. Pulmonary fibrosis is the highest independent predictor of mortality, yet currently there are…Abstract Number: 1902 • 2017 ACR/ARHP Annual Meeting
A Pattern of Higher Serum Levels of IL-10 and MMP-3, Along with Lower IL-6R, Identify RA Patients with Interstitial Lung Disease
Background/Purpose: The pathogenesis and prediction of RA-associated interstitial lung disease (ILD), an extra-articular manifestation with high morbidity and mortality, is poorly understood. We explored the…Abstract Number: 2669 • 2017 ACR/ARHP Annual Meeting
Microvascular Flow Assessed By Dynamic Optical Coherence Tomography: First Non-Invasive Quantitative Outcome Measure of Microvascular Disease in Systemic Sclerosis
Background/Purpose: Virtual skin biopsy by Optical Coherence Tomography (OCT) has been proposed as quantitative outcome measure of fibrosis in Systemic Sclerosis (SSc). Dynamic OCT (D-OCT)…Abstract Number: 466 • 2017 ACR/ARHP Annual Meeting
Plasma Cytokines at Diagnosis May Predict Non-Response to Methotrexate in Patients with Early Rheumatoid Arthritis
Background/Purpose: Methotrexate (MTX) is the first line treatment for patients with rheumatoid arthritis (RA). For over 30% of patients, MTX fails to diminish DAS28 score…Abstract Number: 771 • 2017 ACR/ARHP Annual Meeting
Serological Biomarkers of Collagen Formation Is Increased in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a multisystem, autoimmune disease characterized by immune dysregulation, vasculopathy and excessive fibrosis of the skin and internal organs. Fibrosis is…Abstract Number: 1322 • 2017 ACR/ARHP Annual Meeting
Tissue Folate Dysregulation Is Associated with Disease Activity and Methotrexate Response in Collagen-Induced Arthritis
Background/Purpose: Methotrexate (MTX) is an anti-metabolite inhibitor of folate-dependent biochemical pathways and is effective in reducing disease activity in autoimmune arthritis. This work seeks to…
- « Previous Page
- 1
- …
- 71
- 72
- 73
- 74
- 75
- …
- 109
- Next Page »
